Jeffrey L. Anderson, MD, FACC, FAHA, Chair 

Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect 

Nancy M. Albert, PhD, RN, FAHA

Biykem Bozkurt, MD, PhD, FACC, FAHA

Ralph G. Brindis, MD, MPH, MACC

Mark A. Creager, MD, FACC, FAHA[#][1]

Lesley H. Curtis, PhD, FAHA

David DeMets, PhD[#][1]

Robert A

/pdf/2014-aha-acc-hrs-guideline-for-the-management-of-patients-1v8ficsqox.pdf

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society

March 5, 2019 e1 WRITING GROUP MEMBERS Emelia J. Benjamin, MD, ScM, FAHA, Chair Paul Muntner, PhD, MHS, FAHA, Vice Chair Alvaro Alonso, MD, PhD, FAHA Marcio S. Bittencourt, MD, PhD, MPH Clifton W. Callaway, MD, FAHA April P. Carson, PhD, MSPH, FAHA Alanna M. Chamberlain, PhD Alexander R. Chang, MD, MS Susan Cheng, MD, MMSc, MPH, FAHA Sandeep R. Das, MD, MPH, MBA, FAHA Francesca N. Delling, MD, MPH Luc Djousse, MD, ScD, MPH Mitchell S.V. Elkind, MD, MS, FAHA Jane F. Ferguson, PhD, FAHA Myriam Fornage, PhD, FAHA Lori Chaffin Jordan, MD, PhD, FAHA Sadiya S. Khan, MD, MSc Brett M. Kissela, MD, MS Kristen L. Knutson, PhD Tak W. Kwan, MD, FAHA Daniel T. Lackland, DrPH, FAHA Tené T. Lewis, PhD Judith H. Lichtman, PhD, MPH, FAHA Chris T. Longenecker, MD Matthew Shane Loop, PhD Pamela L. Lutsey, PhD, MPH, FAHA Seth S. Martin, MD, MHS, FAHA Kunihiro Matsushita, MD, PhD, FAHA Andrew E. Moran, MD, MPH, FAHA Michael E. Mussolino, PhD, FAHA Martin O’Flaherty, MD, MSc, PhD Ambarish Pandey, MD, MSCS Amanda M. Perak, MD, MS Wayne D. Rosamond, PhD, MS, FAHA Gregory A. Roth, MD, MPH, FAHA Uchechukwu K.A. Sampson, MD, MBA, MPH, FAHA Gary M. Satou, MD, FAHA Emily B. Schroeder, MD, PhD, FAHA Svati H. Shah, MD, MHS, FAHA Nicole L. Spartano, PhD Andrew Stokes, PhD David L. Tirschwell, MD, MS, MSc, FAHA Connie W. Tsao, MD, MPH, Vice Chair Elect Mintu P. Turakhia, MD, MAS, FAHA Lisa B. VanWagner, MD, MSc, FAST John T. Wilkins, MD, MS, FAHA Sally S. Wong, PhD, RD, CDN, FAHA Salim S. Virani, MD, PhD, FAHA, Chair Elect On behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee

Heart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association

The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)  

Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC  

Endorsed by the European Stroke Organisation (ESO)

/pdf/2016-esc-guidelines-for-the-management-of-atrial-ba0601yb9m.pdf

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

Background: The American Heart Association, in conjunction with the National Institutes of Health, annually reports on the most up-to-date statistics related to heart disease, stroke, and cardiovas...

Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association

/pdf/2016-esc-guidelines-for-the-management-of-atrial-36b2cidm1x.pdf

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO)

Radiofrequency catheter ablation of atrial fibrillation (AF) is an effective rhythm control strategy, and its efficacy has been proved to be superior to anti-arrhythmic drugs.1-3) Recently, the European Society of Cardiology’s 2010 revised guidelines for AF management suggested catheter ablation as the firstline treatment in patients with paroxysmal lone AF.4) When Haissaguerre et al.5) initially reported catheter ablation of AF, it was focal ablation of the pulmonary vein (PV) origin of AF. The rationale for PV ablation was the existence of arrhythmogenic Purkinje fibre-like cells inside the PV,6) and reproducible PV triggers initiating AF.7) In 2002, multipolar circular ring catheter for mapping of the PV was introduced in performing catheter ablation of AF. Multipolar ring catheter is useful for the detection of arrhythmogenic PV and specific localization of foci triggering AF.8) Therefore, multipolar circular ring catheter guided segmental ostial ablation of arrhythmogenic PV was the standard therapy for AF ablation in the early and mid 2000s. However, there is a substantial risk of PV stenosis associated with ostial ablation after RF energy delivery. Therefore to reduce the risk of PV stenosis, the ablation strategy has changed to circumferential PV isolation at the level of PV antrum, which is 10-15 mm outside the PV ostium.9) Although reproducibly defined arrhythmogenic PV isolation demonstrates a clinical outcome comparable with empirical 4-PV isolation,10) most of the patients with AF who underwent catheter ablation have multiple PV foci in multiple veins and hence circumferential bi-antral ablation with electrical isolation of 4 PVs became the cornerstone of catheter ablation of AF.

/pdf/large-circular-ring-catheter-ablation-versus-anatomically-1z41nts7ym.pdf

Large circular ring catheter ablation versus anatomically guided ablation of atrial fibrillation: back to the future for successful catheter ablation of atrial fibrillation?

Catheter ablation is the most effective rhythm control method for patients with atrial fibrillation (AF); however, it inevitably causes atrial tissue damage. We previously reported that AF catheter ablation (AFCA) increases left atrial (LA) pressure without changes in symptom scores. We hypothesized that extensive LA ablation increased the risk of stiff LA physiology. We included 1,720 patients (69.1% male, 60.0 [53.0-68.0] years old, 66.2% with paroxysmal AF) who underwent de novo AFCA and echocardiography before and 1-year after the procedure. Stiff LA physiology was defined, when the amount of the estimated pulmonary arterial pressure increase between the pre-procedural and the 1-year post-procedural follow-up echocardiography was >10 mmHg and when right ventricular systolic pressure (RVSP) was >35 mmHg at 1-year follow-up echocardiography. The failed rhythm control within 1 year was defined as recurrent AF despite using anti-arrhythmic drugs or cardioversion within a year of AFCA. We explored the incidence and risk factors for stiff LA physiology and the rhythm outcome of AFCA. Among the 1,720 patients, 64 (3.7%) had stiff LA physiology 1 year after AFCA. Stiff LA physiology was independently associated with diabetes (odds ratio [OR], 2.36 [95% CI, 1.14-4.87], p = 0.020), the ratio of the peak mitral flow velocity of the early rapid filling to the early diastolic velocity of the mitral annulus (E/Em; OR, 1.04 [95% CI, 1.00-1.10], p = 0.049), LA pulse pressure (Model 2: OR, 1.05 [95% CI, 1.00-1.11], p = 0.049), low LA voltage (OR, 0.36 [95% CI, 0.18-0.74], p = 0.005), empirical extra-pulmonary vein (PV) LA ablation (OR, 2.60 [95% CI, 1.17-5.74], p = 0.018), and radiofrequency (RF) ablation duration (Model 2: OR, 1.02 [95% CI, 1.01-1.03], p = 0.003). Although the incidence of post-AFCA stiff LA physiology was 3.7% and most of the cases were subclinical, the empirical extra-PV ablation was associated with this undesirable condition. In addition, patients who had low mean LA voltage before AFCA could be susceptible to stiff LA physiology.

/pdf/risk-factors-for-stiff-left-atrial-physiology-1-year-after-u2zis8ib97.pdf

Risk Factors for Stiff Left Atrial Physiology 1 Year After Catheter Ablation of Atrial Fibrillation.

The present invention relates to a system and a method for evaluating an effect of an antiarrhythmic agent The present invention includes: an action potential measurement unit that measures a patient′s cardiac action potential; an ion channel property determination unit that determines the patient′s ion channel property by using the measured action potential; and an antiarrhythmic agent effect evaluation unit that performs a simulated treatment effect evaluation by reflecting an antiarrhythmic agent property in the determined ion channel property of the patient According to the present invention, the ion channel property can be determined in a convenient manner by the measurement of the patient′s cardiac action potential, and thus a risk associated with the necessity of extraction of the patient′s myocardial cell can be prevented In addition, the antiarrhythmic agent, which varies significantly in terms of effect and safety depending on individual ion channel properties, does not necessarily have to be used directly in the patient in performing the simulated treatment effect evaluation

System and method for evaluating of antiarrhythmic agents

Impact of Obstructive Sleep Apnea on the Atrial Electromechanical Activation Time(Arrhythmia/Electrophysiology)

Introduction The incidence of arrhythmia is higher in patients with congenital heart disease than in those with a structurally normal heart. Scar-related arrhythmias are common long after cardiac surgery for congenital heart disease. The Mustard operation is a kind of an atrial switch operation that was performed in patients with transposition of the great arteries (TGA). However, the incidence of atrial tachyarrhythmia is high in patients who have undergone this operation. We describe a case of intraatrial reentrant tachycardia (IART) originating from the prior suture line of the baffle in a patient who had undergone the Mustard operation 10 years previously. To treat the IART, ultra-high-density 3-dimentional (3-D) electroanatomic mapping and radiofrequency catheter ablation (RFCA) were performed.

Intraatrial reentrant tachycardia originating from the prior suture line of the baffle in a patient who underwent the Mustard operation: Ultra-high-density 3-dimensional mapping

Hui Nam Pak

Papers

Large circular ring catheter ablation versus anatomically guided ablation of atrial fibrillation: back to the future for successful catheter ablation of atrial fibrillation?

Risk Factors for Stiff Left Atrial Physiology 1 Year After Catheter Ablation of Atrial Fibrillation.

System and method for evaluating of antiarrhythmic agents

Impact of Obstructive Sleep Apnea on the Atrial Electromechanical Activation Time(Arrhythmia/Electrophysiology)

Intraatrial reentrant tachycardia originating from the prior suture line of the baffle in a patient who underwent the Mustard operation: Ultra-high-density 3-dimensional mapping